Creative Medical Technology Holdings Past Earnings Performance
Past criteria checks 0/6
Creative Medical Technology Holdings's earnings have been declining at an average annual rate of -1.5%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 25.5% per year.
Key information
-1.5%
Earnings growth rate
100.4%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -25.5% |
| Return on equity | -51.1% |
| Net Margin | -58,739.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Creative Medical Technology Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -5 | 4 | 2 |
| 30 Sep 23 | 0 | -10 | 3 | 7 |
| 30 Jun 23 | 0 | -9 | 3 | 6 |
| 31 Mar 23 | 0 | -10 | 4 | 7 |
| 31 Dec 22 | 0 | -10 | 4 | 6 |
| 30 Sep 22 | 0 | -8 | 4 | 1 |
| 30 Jun 22 | 0 | -9 | 4 | 1 |
| 31 Mar 22 | 0 | -10 | 4 | 0 |
| 31 Dec 21 | 0 | 19 | 3 | 0 |
| 30 Sep 21 | 0 | -16 | 2 | 0 |
| 30 Jun 21 | 0 | -13 | 1 | 0 |
| 31 Mar 21 | 0 | -12 | 1 | 0 |
| 31 Dec 20 | 0 | -36 | 1 | 0 |
| 30 Sep 20 | 0 | -3 | 1 | 0 |
| 30 Jun 20 | 0 | -6 | 1 | 0 |
| 31 Mar 20 | 0 | -4 | 1 | 0 |
| 31 Dec 19 | 0 | -8 | 1 | 0 |
| 30 Sep 19 | 0 | -1 | 1 | 0 |
| 30 Jun 19 | 0 | -1 | 1 | 0 |
| 31 Mar 19 | 0 | -7 | 1 | 0 |
| 31 Dec 18 | 0 | -14 | 1 | 0 |
| 30 Sep 18 | 0 | -17 | 1 | 0 |
| 30 Jun 18 | 0 | -16 | 1 | 0 |
| 31 Mar 18 | 0 | -10 | 1 | 0 |
| 31 Dec 17 | 0 | -3 | 1 | 0 |
| 30 Sep 17 | 0 | -1 | 1 | 0 |
| 30 Jun 17 | 0 | -2 | 1 | 0 |
| 31 Mar 17 | 0 | -1 | 1 | 0 |
Quality Earnings: CELZ is currently unprofitable.
Growing Profit Margin: CELZ is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CELZ is unprofitable, and losses have increased over the past 5 years at a rate of 1.5% per year.
Accelerating Growth: Unable to compare CELZ's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CELZ is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: CELZ has a negative Return on Equity (-51.11%), as it is currently unprofitable.